Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein
暂无分享,去创建一个
Michael C. Ostrowski | M. McArthur | B. Liu | P. Lin | Yun Zhang | G. Lozano | S. Xiong | M. Ostrowski | Ruli Gao | R. Pourebrahim
[1] G. Lozano,et al. Mutant p53 partners in crime , 2017, Cell Death and Differentiation.
[2] Xuetao Cao,et al. Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils. , 2016, Cancer cell.
[3] Y. Haupt,et al. Faculty Opinions recommendation of Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. , 2015 .
[4] A. Børresen-Dale,et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells , 2015, Genes & development.
[5] V. Rotter,et al. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53 , 2014, Proceedings of the National Academy of Sciences.
[6] Y. Kunisaki,et al. Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. , 2014, Developmental cell.
[7] Karen H. Vousden,et al. Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.
[8] David M. Thomas,et al. Genome-wide Association Study Identifies Two Susceptibility Loci for Osteosarcoma , 2013, Nature Genetics.
[9] Thierry Soussi,et al. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis , 2012, Nucleic Acids Res..
[10] V. Rotter,et al. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species , 2012, Journal of Cell Science.
[11] V. Beneš,et al. Df31 protein and snoRNAs maintain accessible higher-order structures of chromatin. , 2012, Molecular cell.
[12] Nadav S. Bar,et al. Landscape of transcription in human cells , 2012, Nature.
[13] Roberta Galli,et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response , 2012, Proceedings of the National Academy of Sciences.
[14] A. El‐Naggar,et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. , 2012, Cancer cell.
[15] P. Brousset,et al. Specific small nucleolar RNA expression profiles in acute leukemia , 2012, Leukemia.
[16] I. Kubacka,et al. Mutant p53 cooperates with ETS2 to promote etoposide resistance. , 2012, Genes & development.
[17] T. Visakorpi,et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer , 2012, Oncogene.
[18] A. Levine,et al. Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway , 2012, Cell.
[19] F. Farzaneh,et al. Are snoRNAs and snoRNA host genes new players in cancer? , 2012, Nature Reviews Cancer.
[20] S. Hochreiter,et al. cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate , 2012, Nucleic acids research.
[21] J. Makarova,et al. SNOntology: Myriads of novel snornas or just a mirage? , 2011, BMC Genomics.
[22] M. Behlke,et al. Small nucleolar RNAs U32a, U33, and U35a are critical mediators of metabolic stress. , 2011, Cell metabolism.
[23] R. Weinberg,et al. A Perspective on Cancer Cell Metastasis , 2011, Science.
[24] Julie A. Wilkins,et al. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma , 2010, The Journal of pathology.
[25] V. Rotter,et al. Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.
[26] Paul Timpson,et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.
[27] J. Norman,et al. Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.
[28] Michael C. Ostrowski,et al. Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. , 2009, Blood.
[29] Xiaohui Xie,et al. MotifMap: a human genome-wide map of candidate regulatory motif sites , 2009, Bioinform..
[30] M. Bouxsein,et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage , 2008, Proceedings of the National Academy of Sciences.
[31] F. Alt,et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. , 2008, Genes & development.
[32] P. Platzer,et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. , 2007, The New England journal of medicine.
[33] A. McMahon,et al. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors , 2006, Development.
[34] A. Puisieux,et al. Metastasis: a question of life or death , 2006, Nature Reviews Cancer.
[35] Stephen N. Jones,et al. Osteoblast differentiation and skeletal development are regulated by Mdm2–p53 signaling , 2006, The Journal of cell biology.
[36] S. Stamm,et al. The snoRNA HBII-52 Regulates Alternative Splicing of the Serotonin Receptor 2C , 2006, Science.
[37] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[38] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[39] A. Berns,et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.
[40] C. Hauser,et al. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness , 2000, Oncogene.
[41] A. Berns,et al. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. , 2000, Genes & development.
[42] Tamás Kiss,et al. Site-Specific Ribose Methylation of Preribosomal RNA: A Novel Function for Small Nucleolar RNAs , 1996, Cell.
[43] J. Steitz,et al. A mammalian gene with introns instead of exons generating stable RNA products , 1996, Nature.
[44] A. Børresen-Dale,et al. Mutant p 53 cooperates with the SWI / SNF chromatin remodeling complex to regulate VEGFR 2 in breast cancer cells , 2015 .
[45] Jean Louis Fournier,et al. The TP 53 website : an integrative resource centre for the TP 53 mutation database and TP 53 mutant analysis , 2012 .
[46] Magali Olivier,et al. TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.
[47] M. Olivier,et al. TP 53 Mutations in Human Cancers : Origins , Consequences , and Clinical Use , 2009 .
[48] W. Winkelmann,et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.